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Abstract We have investigated the involvement of human
apolipoprotein A-IV (apoA-IV) in gastric acid secretion and
ulcer formation in recently generated apoA-IV transgenic mice.
Compared to control littermates, transgenic animals showed a
gastric acid secretion decreased by 43^77% whereas only slight
variations were observed in the different cell population densities
within the gastric mucosa. In addition, no variation in gastrin
levels was observed. Transgenics were protected against indo-
methacin-induced ulcer formation, with lesions diminishing by
45 to 64% compared to controls. These results indicate that
endogenous apoA-IV expression can regulate gastric acid
secretion and ulcer development.
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1. Introduction
Nutrition processes involve several steps such as appetite/
satiety, feeding, digestion, nutriment absorption and distribu-
tion to the di¡erent tissues of the body. Although it is well
known that these mechanisms are associated and co-regulated
at di¡erent levels, the links between them are still not clearly
determined. Apolipoprotein A-IV (apoA-IV) is a plasma pro-
tein involved in lipid absorption and lipid transport. Plasma
levels of apoA-IV are increased by dietary lipid in postpran-
dial periods [1]. This secretion increase has been proposed to
be involved in the regulation of nutrition processes [2]. It have
been observed that injection of the protein in the brain in-
duced satiety [3], decreased gastric acid secretion [4,5] and
reduced gastric ulceration in rats [6]. All these results sug-
gested that apoA-IV could be involved in feeding behavior
and in gastric physiology. However, no feeding behavior al-
terations were observed in apoA-IV genetically modi¢ed mice
[7,8].
We have recently created transgenic mice overexpressing
human apoA-IV (hapoA-IV) [9]. In the current study, we
mainly focused on the role this apolipoprotein might play in
gastric acid secretion and ulcer protection. Our results showed
that expression of human apoA-IV in transgenic mice de-
creases gastric acid secretion without alteration of the gastric
mucosa and gastrin levels and protects against indomethacin-
induced lesions.
2. Materials and methods
2.1. Mice
Two human apoA-IV transgenic mice lines, (lines 8018 and 8021)
were analyzed [9]. Mice were housed under temperature- and light/
dark (7 am^7 pm) controlled conditions. Animals had free access to
mouse chow diet (UAR, France diet, France) and to water. Plasma
human apoA-IV concentrations were quanti¢ed, in fed or 8 h fasted
animals, by immunoelectrophoresis (hydragel SEBIA, France) using
speci¢c antibodies.
2.2. Gastric acid secretion
Gastric juices were collected using the pylorus ligation method [10].
Brie£y, mice were anaesthetized after 18 h of fasting, the abdominal
cavity was opened and the stomach exposed. Then, the pylorus was
ligated and the cavity closed. After 4 h, the mice were killed, the
gastric content was collected and its volume measured. An aliquot
was titrated with NaOH to determine gastric acid production.
2.3. Extraction and radioimmunoassay (RIA) for gastrin
For extraction of tissular gastrin, frozen gastric tissues were
thawed, boiled in 1 ml of distilled water for 5 min., homogenized
and centrifuged at 5000Ug for 20 min. The supernatants were recov-
ered and used in subsequent RIA. For plasma gastrin, blood samples
were collected on ice with heparin. The serum was stored at 320‡C
until assayed. RIA was performed in duplicate using an anti-gastrin
rabbit antibody (Peninsula, Laboratories, Belmont, USA) and 125I-
gastrin (Amersham, France) as tracer, respectively. The gastrin anti-
serum recognizes the large C-terminal gastrin and all forms of gastrin.
The separation was performed using the double antibody-PEG pre-
cipitation technique. Gastrin concentrations were determined using
human gastrin-17 (Sigma, St. Louis MO, USA) and expressed in
pg/ml or pg/g tissue.
2.4. Histological analysis
Stomachs were pinned £at. After ¢xation in Bouin’s solution, the
secreting surface of the stomach was measured [11]. Two parallel
strips were resected from standardized areas in the fundic and antral
mucosa. Tissues were cut into 4-Wm thick sections, perpendicular to
the mucosal surface. Fundic mucosal sections were stained by hema-
lum-eosin and the mucosal thickness was determined at regular inter-
vals using a calibrated ocular grid 240 Wm wide at 400Umagni¢cation.
Acid-secreting parietal cells were identi¢ed by their position along the
edge of fundic glands, their round shape, the central location of the
large nucleus and their very eosinophilic cytoplasm. Fundic argyrophil
endocrine cells, including enterochroma⁄n-like (ECL) cells, were
stained by the Grimelius argyrophilia. Antral gastrin and somatosta-
tin endocrine cells were immuno-histochemically detected with speci¢c
antibodies using the avidin-biotin complex Vectastain (Vector Labs,
Burlingame, CA, USA) and nuclei counterstained with hemalum. Cell
densities were estimated by counting only nucleated cells throughout
the fundic or antral mucosal thickness, using the ocular grid at
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400Umagni¢cation [11]. Results are expressed in number of nucleated
cells per millimeter of mucosal length.
2.5. Indomethacin-induced gastric ulcers
Four-month-old mice were fasted 8 h prior to subcutaneous admin-
istration of a single dose of indomethacin (Sigma, 200 Wg/g of body
weight). The mice were killed 18 h later; the stomachs removed,
opened and ¢xed in 10% bu¡ered neutral formalin. Images of the
glandular stomach were digitalized and surfaces were calculated in a
computer-assisted analysis system. Percentage of ulcerated area was
determined by calculating the ratio of ulcerated surface to total mu-
cosal surface.
2.6. Statistical analysis
Non-transgenic littermates were used as control mice in all experi-
ments. All biological data are expressed as mean þ S.E.M. Data were
analyzed by Fisher’s PLSD multiple comparisons ANOVA tests or,
for histological data, by the Student’s t-test.
3. Results and discussion
3.1. Gastric acid secretion and gastrin levels
We have recently generated apoA-IV transgenic mice [9].
For these studies two transgenic lines were used, a low ex-
pressor (line 8021) and a high expressor (line 8022) with re-
spectively 34 þ 6 mg/dl and 140 þ 29 mg/dl of human plasma
apoA-IV. We analyzed if plasma levels of the protein were
increased in postprandial conditions in these transgenics. In-
deed, a 2.3-fold and a 2.0-fold increase were observed in lines
8021 and 8022, respectively in fed condition and fasted levels
(Fig. 1). In consequence these mice displayed the up-regula-
tion of apoA-IV plasma levels currently observed in fed con-
ditions. The growing curves of 8021 and 8022 transgenic mice,
as well as their feeding behavior, were similar with those ob-
served with the non-transgenic control littermates (data not
shown).
Afterwards, gastric acid secretion was analyzed by the py-
lorus-ligated method. Secretion was reduced by 43%
(P6 0.05) in the line 8021 and by 64% (P6 0.01) in the line
8022 when compared to control mice (Fig. 2A). In order to
determine if this hypo-secretion was maintained at older ages,
we also analyzed 9-month old mice. Plasma levels of apoA-IV
were found to be the same as from those observed at 2
months. A gastric acid secretion reduction of 77%
(P6 0.001) and of 45% (P6 0,05) was observed in lines
8021 and 8022, respectively when compared to control mice
(Fig. 2B). Di¡erences of gastric acid output between the two
transgenic lines were not signi¢cant neither in 2-month
(P = 0.28) nor in 9-month old mice (P = 0.16). This suggests
that gastric secretion inhibition is dependent neither of human
apoA-IV plasma concentration nor of the age of the animals.
It is possible that a maximum e¡ect might be obtained with
protein concentrations lower than those present in the trans-
genic mice. Thus, our results indicate that endogenous expres-
sion of human apoA-IV inhibits gastric acid secretion in our
mice.
Since gastrin is a major secretagogue for gastric acid secre-
tion, we investigated gastrin levels in plasma and in gastric
tissue. No signi¢cant variations were found. Plasma gastrin
levels were 16.6 þ 0.4 pg/ml and 16.0 þ 0.6 pg/ml in control
and transgenic mice, respectively, while tissular gastrin levels
were 134.7 þ 26.4 pg/g and 128.3 þ 29.0 pg/g in each group of
animals. These results showed that gastric acid secretion was
decreased in transgenic mice without any change in plasma
and tissular gastrin levels, suggesting that other regulatory
pathways are involved in secretion regulation by apoA-IV.
3.2. Gastric morphology
Anatomic variations could be induced by the expression of
the transgene and might explain the di¡erences observed in
gastric acid secretion. To further elucidate the mechanism of
action of apoA-IV in gastric acid secretion we analyze the
architecture of gastric mucosa in apoA-IV transgenic mice.
Histological studies were undertaken in the previously ana-
lyzed 2- and 9-month old control and transgenic mice line
8021, where gastric secretion inhibitions were 43% and 77%,
respectively. The surface of the secreting stomach and the
fundic mucosal thickness showed no di¡erences between
transgenic and wild-type mice (Table 1). Densities of cells
implicated either in gastric acid secretion or its regulation
were relatively unchanged (Fig. 3). In transgenic apoA-IV
mice, parietal cells decreased by 10% and by 15% not signi¢-
cant (NS) at 2 and 9 months respectively. Decreases were of
the same order at the two states of life for fundic argyrophil
and somatostatin cells. Mean gastrin cell density which
showed a 16% decrease at 2 months (NS) was strictly normal
at 9 months. All these results indicate that the morphological
architecture of the gastric mucosa remained roughly normal
even after 9 months of life. Other genetically modi¢ed animals
Fig. 1. Human apoA-IV levels in fasted and fed condition. Plas-
matic levels of human apoA-IV were measured in 8-h fasted and
fed conditions in the two transgenic lines (8021 and 8022). n = num-
bers of animals used for each experiment. P values of fasted vs. fed
are: * = P6 0.05, *** = P6 0.001.
Table 1
Morphometric results in the gastric mucosa of wild-type and transgenic mice at two stages of life
Parameters 2 Months 9 Months
Wild-type (n = 6) Transgenics (n = 6) Wild-type (n = 5) Transgenics (n = 6)
Stomach surface (cm2) 2.81 þ 0.12 2.89 þ 0.12 3.19 þ 0.04 3.23 þ 0.8
Fundic mucosal thickness (Wm) 223 þ 7 206 þ 10 212 þ 13 216 þ 16
Transgenic mice were from line 8021. n = number of animals used for each experiment.
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displaying gastric hypo-secretion have showed marked gastric
histological changes. In transgenic mice overexpressing trans-
forming growth factor alpha, inhibition of gastric acid secre-
tion was accompanied by severe adenomatous hyperplasia
that resulted in striking hypertrophy of the mucosa [12,13].
Knock out mice for gastrin in which basal and stimulated
gastric acid secretion were abolished showed a clear-cut de-
crease in parietal and enterochroma⁄n-like (ECL) cells num-
bers (323 to 346%) [14,15]. In cholecystokinin-B/gastrin re-
ceptor-de¢cient mice, decreased acid production (370%) was
accompanied by an increase in the antral gastrin cell number
consistent with the concomitant elevation in circulating gas-
trin. Moreover parietal and enterochroma⁄n-like cells (ECL
cells) were decreased by 30^50% in these mice, providing a
likely explanation for the reduction in acid output [16,17]. In
contrast, overexpression of hapoA-IV, and the observed de-
creased gastric acid secretion, could not be signi¢cantly asso-
ciated with important alterations of the structure of the gas-
tric mucosa and of gastrin levels. Nevertheless, we cannot
exclude that the slight variations observed in the number of
functional cells in transgenics were related to the overexpres-
sion of human apoA-IV.
3.3. Indomethacin induced ulcer formation
To speci¢cally investigate if apoA-IV plays a role in gastric
ulcer development, ulcer formation was next assessed in these
transgenic mice. Gastric ulcers were induced with indometha-
cin (200 mg/kg). All the lesions were located in the glandular
stomach. In both transgenic lines, the total ulcerated surfaces
were signi¢cantly smaller than in controls (Fig. 4). Reductions
in lesion area were 64% and 45% in 8021 and 8022 mice,
respectively. The degree of mucosa ulceration was of the
same order in transgenics and in control littermates. This
result clearly shows that expression of hapoA-IV is associated
with a reduction in indomethacin-induced ulceration. The re-
duction seems not to be dependent on plasma concentration
of human apoA-IV as no signi¢cant di¡erences in the ulcer
surfaces were observed between the low (8021) and the high
(8022) apoA-IV expressor lines. As for gastric acid secretion,
it is possible that maximum e¡ect on ulcer protection can be
obtained with apoA-IV concentrations lower than those
present in these transgenic mice. Even if supplementary data
are necessary to understand the mechanism of ulcer protection
by apoA-IV, it is tempting to hypothesize that the decrease of
lesion area may be related to the reduction of the gastric acid
secretion in the transgenic mice.
In conclusion, this paper clearly shows a physiological link
between apoA-IV endogenous expression and gastric acid se-
cretion. The animal model presented here can be a useful tool
for the study of apoA-IV up-regulation under postprandial
Fig. 3. Numerical densities of nucleated cells implicated in acid secretion in the gastric mucosa of wild-type and transgenic mice. A and B rep-
resent values at 2- and 9-month-old mice, respectively. Transgenic mice are from line 8021. Values are mean þ S.E.M. Five or six animals were
used for each experiment.
Fig. 2. Gastric acid secretion of 2- and 9-month-old mice. Bars indi-
cate the gastric acid secretion in control mice and in 8021 and 8022
transgenic animals. A and B represent values at 2 and 9 month old
mice, respectively. n = numbers of animals used for each experiment.
P values of transgenics vs. controls are: * = P6 0.05, ** = P6 0.01
and *** = P6 0.001. The di¡erences between secretion values of
2- and 9-month-old animals were not signi¢cant.
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conditions. Furthermore, our results underline the interest of
studying diets or drugs that modify apoA-IV expression in
relationship with gastric secretion or ulcer formation.
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Fig. 4. Indomethacin-induced gastric ulcers. Ulcers were induced by
injection of indomethacin (200 Wg/g wt). Bars represent the percent
of ulcerated areas of each category: control mice or 8021 and 8022
transgenic mice. n = numbers of animals used for each experiment.
P values of transgenics vs. controls are: * = P6 0.05 and
** = P6 0.01.
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